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Abstract  1 
Aim 2 
Recovery and trainability of impaired selective voluntary motor control (SVMC) of the 3 
lower extremity in children with upper motor neuron lesions (UMN) has received little 4 
attention. To facilitate an evidence-based debate about this topic, this review evaluates 5 
the evidence level of the psychometric properties of SVMC measures. 6 
Method 7 
MEDLINE, EMBASE, CINAHL, PsycINFO and SCOPUS databases were systematically 8 
searched up to July 2016. Two independent raters scored the methodological quality in 9 
accordance to the COnsensus-based Standards for the selection of health 10 
Measurement INstruments (COSMIN) checklist. The overall level of evidence was 11 
scored according to Cochrane criteria. 12 
Results  13 
We identified 3590 studies of which 17 were included. COSMIN scores ranged from 14 
‘poor’ to ‘excellent’ for studies investigating measurement properties of the ‘Selective 15 
Motor Control (SMC) test’, ‘modified Trost-test’, ‘Gillette’s SMC test’, ‘Selective Control 16 
Assessment of the lower Extremity’ (SCALE), kinematic measures, electromyography, 17 
and torque steadiness. Studies assessing the SCALE scored highest on COSMIN 18 
items. Evidence levels for SCALE’s validity and reliability properties were ’moderate’ 19 
while for the other SVMC measures these ranged from ‘unknown’ to ‘moderate’. 20 
Responsiveness was not assessed. 21 
Interpretation 22 
Further psychometric studies of SVMC measures are needed to provide a scientifically 23 
contribution to the ongoing debate of SVMC trainability.   24 
 25 
Shorted title:    Psychometric properties of SVMC measures 26 
‘What this paper adds’:   27 
• Very few studies evaluate validity and reliability of 28 
SVMC measures  29 
• Responsiveness studies of SVMC measures are 30 
lacking 31 
• We can currently recommend the ‘SCALE’ 32 
measure/tool 33 
• The evidence level of objective interval-scaled 34 
SVMC measures is limited  35 
• Further rigorous psychometric studies of SVMC 36 
measures are needed 37 
 38 
 39 
 40 
 41 
Introduction 1 
Understanding and therapeutically guiding motor development and motor control is a 2 
complex and challenging topic for professionals and caregivers within the field of 3 
neuropediatric rehabilitation.1-3 Motor control is a primary determinant for moving 4 
physiologically or ‘normally.4 Measuring motor control regards  the question ‘how are 5 
motor units selected, activated and deactivated’.5 In children with upper motor neuron 6 
(UMN) lesions, the muscle control mechanism of selected activation and deactivation is 7 
often disturbed and causes non-physiological movements (patterns).3,6 Clinically, this is 8 
known as a loss of selective voluntary motor control (SVMC).6-8 Selective motor control 9 
is defined as the ability ‘to isolate the activation of muscles in a selected pattern in 10 
response to demands of a voluntary movement or posture’. 8 The term ‘voluntary’ within 11 
SVMC emphasises the deliberate performance of selected muscle activation during 12 
functional tasks.7 13 
Pathophysiologically, a loss of SVMC is related to impaired descending corticospinal 14 
input, which results in disturbed control of spinal networks.6,8 Complex muscle activation 15 
patterns of agonist, synergist, and antagonist are disturbed.8,9 This allows the 16 
appearance of flexor and/or extensor mass movement patterns (i.e. synergies), which 17 
often limits the patient’s control of movement.7 For patients with a complete loss of 18 
SVMC, strength and functional training is only possible within synergies, potentially 19 
accompanied by co- and mirror movements of other muscle groups. This could limit the 20 
patient’s ability to increase or maintain strength of a specific weak muscle (group).6-9 21 
Therefore, in the long term, impaired SVMC can result in a vicious circle of limited motor 22 
performance during daily life activities, secondary deformities, and pain.6,7,10 Studies 23 
investigating the impact of different motor impairments in children with cerebral palsy 24 
(CP) have shown that a loss of SVMC limits motor performance more than other 25 
routinely measured impairments such as spasticity and/or contractures.10-13 Just 26 
recently, selective motor control has been listed in the International Classification of 27 
Functioning, Disability and Health-Children & Youth (ICF-CY) core sets for children and 28 
youth with CP (b7600),14 underscoring its clinical importance within this patient group. 29 
Furthermore, for many ambulatory children with UMN lesions and their caregivers, 30 
learning to walk/move ‘normally’ (i.e. within a physiological pattern or without synergistic 31 
mass patterns) is a commonly mentioned rehabilitation goal.15,16 Although for achieving 32 
a ’normalized’ walking pattern training of multiple body functions (e.g. balance, strength) 33 
is necessary, SVMC plays a major role in performing qualitative good walking 34 
movements.13  35 
Despite the social and pathophysiological importance of SVMC, evidence about its 36 
trainability in children with CP is relatively limited.17-20 One possible reason for the small 37 
number of intervention studies to improve SVMC might be related to the challenges of 38 
measuring motor control.7 In contrast to measuring motor function, which is readily done 39 
in numbers by asking ‘how fast’ or ‘how often’ a movement is performed, measuring 40 
motor control is more difficult as it looks on ‘how’ the movement is controlled and 41 
executed.1,2,7  Nevertheless, for being able to assess rehabilitation (medical/ 42 
therapeutically) induced changes of SVMC the availability of valid, reliable, and 43 
responsive SVMC outcome measures are fundamental.  44 
As no systematic review of the psychometric properties of SVMC measures for the 45 
lower extremity for children with UMN lesions exists, the purpose of this study was to 46 
address this gap. By focusing on the lower extremity, we aimed to extend the 47 
observations from a recent systematic review21 which investigated psychometric 48 
properties of tests scoring either compensatory or physiological movements of the 49 
upper extremity in children with UMN lesions. Providing an overview of SVMC 50 
measures for the lower extremity and the evaluation of the level of evidence of the 51 
psychometric properties of SVMC measures for children with UMN lesion will be useful 1 
for clinicians and researchers planning future studies on the trainability of SVMC.  2 
Method 3 
Search Strategy  4 
To identify studies assessing the psychometric properties of outcome measures of 5 
SVMC in children with an UMN lesion the following databases were searched without 6 
any time limit until July 2016: MEDLINE, EMBASE, CINAHL, PsycINFO, SCOPUS, 7 
Cochrane and PEDro. The search strategy included keywords and synonyms for SVMC 8 
as well as names of tools previously used to measure SVMC, the population of interest, 9 
and a validated search filter for finding studies on measurement properties.22 Please 10 
see Appendix 1 for an example of the search strategy for MEDLINE. In addition, we 11 
hand-searched the reference lists of the articles included in the review to identify 12 
additional studies. 13 
 14 
Study Selection  15 
We used a previously developed proprietary database (Microsoft Access 2010) to 16 
systematically enter the data and score the methodological quality of the studies.23  17 
Inclusion and exclusion criteria were defined in advance. In accordance to the definition 18 
of SVMC, stated in the introduction, only papers dealing with selective movement of one 19 
joint of the lower extremity or with a primary selective (not synergistic) voluntary multi-20 
joint movement were included. For example, papers dealing with the ankle dorsiflexion 21 
during initial contact or investigating pathological synergy patterns during walking (i.e. 22 
activation of the m. rectus femoris and m. semitendinosus during swing phase) were 23 
included, whereas papers measuring SVMC over the whole gait cycle or during gross 24 
motor coordination tasks were excluded. Considering that SVMC comprehends how 25 
accurately and smoothly someone can isolate the selection of a particular muscle 26 
group, papers describing the measurement of submaximal torque steadiness were 27 
included (i.e. ICF body function level b7300 power of isolated muscle activation). 28 
However, studies on maximal voluntary contraction were excluded, as patients with 29 
impaired SVMC tend to produce maximal force by using mass synergy patterns.24,25 30 
Furthermore, neuroimaging measures, testing structural and metabolic intactness of the 31 
involved underlying neurophysiological structures, or networks involved in SVMC (i.e. 32 
ICF body structure levels 1100 CST, primary cortex) were excluded. Only papers 33 
dealing with children and youths (3 to 21 years) with UMN lesions were included. This 34 
age range was chosen for neurophysiological reasons (e.g. maturation of the 35 
corticospinal tract) and practical reasons (e.g. compliance/understanding). Studies with 36 
the explicit aim to assess one or more psychometric properties were included, as well 37 
as cohort-studies indirectly investigating the psychometric characteristics of an outcome 38 
measure, by for instance looking at the difference between neurological intact children 39 
and those with UMN lesion. All other forms of indirect evidence (i.e. intervention studies) 40 
were excluded. Only manuscripts published in English and German were included for 41 
review.  42 
Two reviewers (J.B. and M.vdL.) independently screened all titles and abstracts of the 43 
papers. In cases of doubt, the full text article was consulted to decide whether or not the 44 
study met the inclusion criteria. A third reviewer was available if no consensus could be 45 
achieved. 46 
Quality Evaluation  47 
Evaluation of the methodological quality of the included papers was carried out 48 
independently by J.B. and M.vdL by using the 4-point rating scale (‘excellent’, ‘good’, 49 
‘fair’, ‘poor’ or ‘not applicable’) of the COnsensus-based Standards for the selection of 50 
health Measurement INstruments (COSMIN) checklist.26 The COSMIN-checklist 51 
consists of three domains, namely validity (‘The degree to which an (HR-PRO) 1 
instrument measures the construct(s) it purports to measure‘), reliability (‘The extent to 2 
which scores for patients who have not changed are the same for repeated 3 
measurement under several conditions‘), and responsiveness (‘The ability of an (HR-4 
PRO) instrument to detect change over time in the construct to be measured‘).26 Each 5 
domain contains one or more measurement properties. The reviewer selects the 6 
measurement properties (COSMIN boxes) evaluated in the study and scores the 7 
specific item-lists via the aforementioned ordinal scoring system. The lowest score of all 8 
items of the chosen COSMIN box determines the overall methodological quality of the 9 
paper. In line with previous COSMIN reviews in the field of neuro-pediatrics, we adopted 10 
the overall COSMIN score by omitting the item regarding sample size.21,23 11 
To ensure that both raters scored the papers in accordance to the guidelines and to 12 
allow other raters to arrive at the same conclusion, the following procedures were 13 
established prior to the independent COSMIN rating: raters familiarized with the 14 
COSMIN manual and terminology, and discussed the scoring of two papers and 15 
established additional rating rules (Appendix 4). Although the COSMIN manual provides 16 
general rules for all boxes and items, for some items, the COSMIN rating is still open to 17 
subjective interpretation, e.g. ‘time interval appropriate’. It is for this reason that 18 
COSMIN itself recommends specification of additional rules for individual reviews.27 If 19 
the two reviewers could not agree on a scoring a third reviewer was available.  20 
For the assessment of quality of the measurement properties, the updated criteria 21 
suggested by Terwee et al.28 were applied (Appendix 2). The overall level of evidence 22 
for each SVMC measure  and each measurement property was evaluated according to 23 
the Cochrane Back Review Group Criteria29 ‘strong’, ‘moderate’, ‘limited’, ‘conflicting’, 24 
‘unknown’ (Appendix 3). This overall score was given  in relation to the methodological 25 
quality of the study and the results of the measurement properties.26 Again, criteria for 26 
sample size were adapted as follows: sample size > 100 subjects of the combined 27 
studies was rated as ‘strong’ [+++ or ---]; sample size between 50-99 was rated as 28 
‘moderate’ [++ or --]; sample size between 25-59 as ‘limited’ [+ or -]; and sample size 29 
fewer than 25 as ‘unknown’ [?].30 30 
 31 
Results 32 
Description of the included studies 33 
The systematic search resulted in 3590 references being identified. Based on the titles 34 
and abstracts, 33 papers were included for full-text reading. After applying the inclusion 35 
and exclusion criteria, 17 papers were retained for review (Fig. 1).  36 
These 17 papers described the measurement properties of four clinical, ordinal-scaled, 37 
assessment tools (Selective Motor Control test (SMC); modified Trost-test (mTrost); 38 
Gillette’s SMC test;  Selective Control Assessment of the lower Extremity (SCALE)) and 39 
three laboratory based interval-scaled measurement tools (kinematic measures, 40 
electromyography (EMG) and torque steadiness). The majority of studies tested SVMC 41 
of the ankle or the knee joint. 42 
The following psychometric properties were evaluated: hypotheses testing/construct 43 
validity was assessed in 17 studies, reliability in six (inter-rater n=5; test-retest n=3; 44 
intra-rater n=1) and both content and criterion validity in one study. Responsiveness 45 
was not evaluated in any study. Most studies tested the SCALE (n=9), followed by 46 
studies evaluating torque steadiness measures (n=2), kinematic measures (n=4), and 47 
EMG of selected lower limb muscles (n=1). The age of the participants in the studies 48 
included for final review ranged from two to 21 years with the exception of one study31 49 
where the oldest participant was 28 years. Although this age range was slightly wider 1 
than the one set by the inclusion criteria (3-21 years), discussing this issue ended in the 2 
common decision for inclusion. As the mean age ranged from 9 years 3 months to 16 3 
years, the youngest and the oldest participant were seen as outliers. Sample size varied 4 
from eight to 51 participants. All studies included children with a diagnosis of cerebral 5 
palsy. In two cohort studies32,33, data of children with CP who had undergone a selective 6 
dorsal rhizotomy were compared to those of a control group children with CP who had 7 
not. Selective dorsal rhizotomy is a neurosurgical procedure, which aims to minimize 8 
the limiting influence of spasticity on motor control in children with spastic CP. The 9 
comparison of SVMC between children with and without rhizotomy was therefore 10 
considered an assessment of the validity of the SVMC tool. Four other cohort 11 
studies31,34-36 investigated the construct validity of the SVMC instrument, by comparing 12 
patients with CP versus participants who were neurologically intact. General 13 
characteristics and clinical utility for each SVMC measure is summarized in Table I. The 14 
methodological quality per measurement property as well as the overall evidence 15 
criteria can be seen in Table II. 16 
Hypotheses testing  17 
Of the 17 papers which evaluated construct validity (‘hypotheses testing’), 10 papers 18 
included clinical assessment tools and seven papers laboratory-based measurement 19 
tools (Table I and II).  20 
Nine of the 10 papers regarding clinical assessment tools evaluated construct validity of 21 
the SCALE. The modified COSMIN scores of three of these 8 SCALE papers were 22 
‘good’,37-39 four were rated as ‘fair’,40-42 one as ‘excellent’,44 and one as ‘poor’.45 Quality 23 
of construct validity was evaluated in accordance to Terwee et al.29 as ‘positive [+]’ in 24 
eight papers37-43 and as mixed ‘positive/negative [+]/[-]’ in one studies,45. Overall, there 25 
was ‘moderate positive [++]’ evidence30 for construct validity of the SCALE in terms of: i) 26 
its correlation with the GMFCS,37,44 a and ii) its proximal-distal concordance (SVMC is 27 
more often and/or more severely impaired in distal body parts).38,44  A ‘limited positive 28 
[+]’ evidence level was given for its validity testing with the Berg Balance Scale43 and for 29 
predicting knee flexion during initial contact during stance phase of gait.42 Three studies 30 
investigated relationships between total limb SCALE scores and knee flexion during 31 
swing phase. Two studies39,40 found significant correlations and one not.41 Therefore, 32 
their level of evidence was rated as ‘conflicting [±]’. In relation to the poor quality of the 33 
Kusumoto et al. study,45 who investigated the relationship between the SCALE and 34 
knee extensor strength, its level of evidence was rated as ‘unknown [?]’. Therefore, this 35 
study did not contribute to the overall evidence level of the SCALE.”  36 
In the other three SVMC clinical assessment tools construct validity was only evaluated 37 
for the Gillette’s SMC test. The study of Manikowska and collaeges31 compared 38 
Gillette’s knee flexion SMC scores in patients with CP versus participants who were 39 
neurologically intact using electromyography. This study received a ‘poor’ modified 40 
COSMIN score, but results were rated as ‘positive [+]’ in accordance to Terwee et al. 29 41 
The level of evidence30 was evaluated as ‘unknown [?]’. 42 
Seven papers investigated construct validity of SVMC using laboratory-based 43 
measurement tools including lower limb kinematics,32,34,39,40 EMG,33 and torque 44 
steadiness.35,36 Two kinematic papers39,40 were already evaluated in relation to the 45 
SCALE’s construct validity in the previous paragraph. We decided to list them under this 46 
sections as well. As there is no gold standard measure for quantifying SVMC, and the 47 
papers are cohort studies investigating the correlation between the SCALE and a 48 
kinematic measures for SVMC, they could be regarded as studies investigating the 49 
construct validity of the SCALE, but also of the kinematic measures, depending on 50 
which measure is regarded as more ‘established’.  As the quality and evidence rating of 51 
the two studies39,40 is the same as presented above, the results will not be repeated 52 
here. Their COSMIN methodological quality was rated as ‘fair’ and quality of construct 1 
validity was rated as ‘positive [+]’ in three studies34,35,36 and as mixed ‘positive/negative 2 
[+]/[-]’ in two32,33. As the sample size was too small (n<25) in three studies, the evidence 3 
level was only scored for one kinematic34 and one EMG33 study. As the results of these 4 
studies were ambiguous in supporting the construct validity of the SVMC measurement 5 
method, a ‘conflicting [±]’ evidence rating was assigned. 6 
Overall, the methodological quality of the majority of the above mentioned studies was 7 
reduced due the absence of a priori formulated hypotheses, thereby limiting their 8 
COSMIN27 as well as validity quality29 scoring. 9 
 10 
Content and Criterion Validity 11 
Content and criterion validity were only assessed for the SCALE (Table II).37,44 COSMIN 12 
rating27 of content validity was considered ‘poor’. Although 14 experts were involved on 13 
item-agreement for statements about content, administration, and grading of the 14 
SCALE, the paper lacked a description whether all items were relevant for the construct 15 
or for the population of interest.37 The quality rating of the results27 was scored as 16 
‘indeterminate [?]’, and the evidence as ‘unknown [?]’. 17 
The method applied to establish criterion validity of the SCALE was rated as 18 
‘excellent’.44 As the Fugl-Meyer Assessment (item III and IV) measures a similar 19 
construct as the SCALE and their correlation exceeded 0.70, the SCALE criterion 20 
validity results were rated as ‘positive [+]’. Therefore, a ‘limited positive [+]’ evidence 21 
level was given for criterion validity of the SCALE. 22 
 23 
Reliability  24 
Reliability was investigated in three (SMC46,47, mTrost47, SCALE37,44) of the four clinical 25 
assessment tools and in two (kinematic32, torque35) of five laboratory-based SVMC 26 
tools. The SMC test-retest reliability was tested in two studies.46,47. The modified 27 
COSMIN27 rating for SMC inter-rater reliability ranged from ‘fair’ 47 to ’good’46. The 28 
methodological quality of inter-rater reliability of the mTrost test was also rated ‘fair’. 47 29 
Inter-rater reliability of the SCALE was tested by two studies and scored as ‘excellent’44 30 
and ‘good’ 37. The SCALE’s intra-rater reliability was further investigated and received a 31 
‘good’ modified COSMIN score.44 The methodological quality of test-retest reliability for 32 
the kinematic32 and torque steadiness35 measure was evaluated as ‘good’. Overall, 33 
studies assessing inter-rater reliability were rated lowest for COSMIN items describing 34 
the statistical procedures (i.e. description of weighted scheme ICC, Kappa). The items 35 
regarding the stability of participants between the two or more assessments and the 36 
description of test conditions were the most limiting items for the four studies on test-37 
retest and intra-rater-reliability.  38 
Applying the quality criteria29 for measurement properties revealed ‘positive [+]’ results 39 
for four reliability studies;32,37,44,46 mixed‘ positive/negative [+]/[-]’ results in three 40 
studies,35,46,47, and negative [-]’ results for inter-rater reliability of the SMC test.  41 
When evaluating the overall evidence level using Cochrane guidelines30, we found 42 
‘moderate positive results [++]’ for the inter- and intra-rater reliability of the SCALE.37,44 43 
‘Moderate negative results [- -]’ were evident for the inter-rater reliability of the SMC46,47   44 
and ‘limited negative results [-]’ for the m-Trost47. Due to the low sample size (n<25) the 45 
evidence level of the test-retest reliability of the kinematic32 and torque steadiness 46 
measurement35 studies was scored as ‘unknown [?]’.  47 
 48 
 49 
Discussion  50 
This review revealed a limited number of psychometric studies investigating SVMC 51 
measures in children with UMN lesions. The overall evidence was further limited as 10 52 
out of 17 studies were cohort studies with a limited methodological quality (i.e. ‘poor’ or 1 
‘fair’) with the exception of one study39 which scored ‘good’ according to modified 2 
COSMIN rating guidelines. No study investigated responsiveness, which we consider a 3 
crucially important measurement property, especially in context of the ongoing debate 4 
about trainability of SVMC. Although we explicitly searched for the whole population of 5 
pediatric UMN lesions, only psychometric studies including children with CP were found. 6 
Therefore, the results of this review are limited to children with CP and cannot be 7 
directly transferred to other children with impaired SVMC (i.e. acquired brain injuries). 8 
The chosen age range (2-21 years) for this review, might have been wide when 9 
considering developmental issues which are known to influence SVMC (e.g. maturation 10 
of CNS function) as well as the importance of the participants’ cognitive understanding 11 
and motivation for the SVMC measurement procedure/testing. Nevertheless, this age 12 
range was chosen due to the overall limited number of studies available for review. 13 
Future studies regarding SVMC measures may choose to investigate psychometric 14 
properties in separate age groups (i.e. pre CNS maturation 2y-7y and post < 8 years). 15 
The SCALE was the most often investigated assessment tool, in terms of number of 16 
studies conducted and in the number of its measurement properties investigated. The 17 
SMC and m-Trorst were only rated on reliability, thus lacking evidence on their validity. 18 
The Gillette’s SMC test was only investigated on its validity, lacking evidence about its 19 
reliability. In terms of psychometric quality, the SCALE had the highest level of evidence 20 
with a moderate positive level of evidence concerning its inter-rater reliability and its 21 
construct validity, and an unknown and limited level of evidence of content and criterion 22 
validity, respectively. Another advantage of the SCALE in comparison to the other 23 
assessment tools (SMC, m-Trost,) lies in its evaluation of five lower extremity joints 24 
rather than one or three joints. In addition, clinical utility (Table I) of the SCALE, as well 25 
as of the other SMC assessment tools, was scored high as time, costs and resources 26 
are low. However, in terms of limitations, the SCALE’s application is limited to children 27 
with spastic CP. Furthermore, as its ordinal scoring system relies on the impression of 28 
the rater (i.e. therapist, consultant), it is a subjective measurement. Finally, the SCALE’s 29 
3 level ordinal scoring system (normal, impaired, and unable) may lack sensitivity to 30 
detect certain therapy-induced changes of SVMC. These limitations (spastic CP, ordinal 31 
scoring system) also apply for the other three clinical tools. 32 
The construct validity of the kinematic, EMG and torque steadiness was assessed, but 33 
none of the papers evaluating these measurement techniques explicitly mentioned that 34 
the assessment of validity was an a priori objective. Because of this, the formulation of 35 
hypotheses was often absent thus diminishing their modified COSMIN score to ‘fair’. 36 
Only two laboratory based SVMC measures (kinematic, torque steadiness)32,35 were 37 
assessed regarding their test-retest reliability. In terms of psychometric quality as well 38 
as clinical utility (see Table I), none of the identified laboratory based measures seem to 39 
offer great advantage over the other. The equipment required to record the outcome 40 
measures was often customized, making it difficult for other groups (researchers or 41 
clinicians) to apply and confirm or extend findings of studies exploring the laboratory 42 
based measures using EMG, kinematics, or torque measurements. Furthermore, the 43 
measurement procedures appear time consuming and complex in comparison to more 44 
routinely applied clinical assessments. Personnel also required extensive training in the 45 
application and analysis of these measures (see Table I).  46 
In summary, the results from this systematic review show the limited level of evidence 47 
regarding the psychometric properties (reliability and validity) and absence of evidence 48 
regarding responsiveness of currently available SVMC measures of the lower extremity 49 
in children with UMN lesions.  50 
 51 
Methodological Considerations  52 
Low inter-rater agreement when rating the quality of the evidence in systematic reviews 1 
(e.g. rating Risk of Bias in Cochrane type reviews) can be an important methodological 2 
issue which should be considered when conducting a systematic review.48 In our review 3 
agreement between the raters for all COSMIN items was high. Only five out of 246 4 
items needed further discussion, and none required the rating of a third reviewer. This 5 
high agreement was likely the result of the specific rating rules which we established as 6 
recommended by the COSMIN group. For example, when scoring the reliability items 4-7 
7 for the SCALE, we decided in advance to score the use of video for the evaluating of 8 
the inter- and intra-rater reliability as appropriate, as this allows a discrete evaluation of 9 
the scoring system by maintaining the stability of test conditions and patient status as 10 
well as saving on time and resources. In contrast, a video approach was not considered 11 
to be appropriate for determining test-retest reliability when the stability of the patient is 12 
evaluated.  13 
In line with other neuro-pediatric COSMIN reviews 22,24,49 we modified the rating of the 14 
sample size item (modified COSMIN score) as the sample size is often limited in clinical 15 
neuro-pediatric studies and not comparable with large scale epidemiological healthcare 16 
studies using patient-reported outcome measures for which the COSMIN guidelines 17 
were initially evaluated. This modified scoring improved the overall rating of all studies 18 
with the exception of the construct and content validity score of the studies from Fowler 19 
et al.37 and Zwaan et al.33 Although we used this modified score, we recommend that 20 
future psychometric studies should include a sufficiently large sample size (>30).  21 
Other reasons for scoring poor were the lack of ‘a priori’ formulated hypotheses (box 22 
‘hypothesis testing’) and for one study37 the lack of evaluating each item separately for 23 
its content validity (box ‘content validity’). While we consider it important that each single 24 
question should be evaluated separately for its content validity in a Health Care 25 
Questionnaire (where the COSMIN was originally developed for), it could be questioned 26 
whether the same rating rules are needed for an assessment tool like the SCALE that 27 
consists of a similar procedure repeated for different joints.  28 
Future research directions 29 
The results of this review show, that the SCALE is the most frequently investigated 30 
assessment method in the population of CP children and also has the highest quality 31 
rating. Its responsiveness to change has not been assessed, but it may be expected 32 
that due to its ordinal scoring system its sensitivity to measure changes of SVMC is 33 
limited. To improve its sensitivity and simultaneously to benefit from its child-friendly 34 
procedure, combining the SCALE with another more sensitive measure appears to be 35 
promising. This idea has also been proposed in previous studies.33,50 While Zwaan et 36 
al.33 found no convincing evidence for detecting extensor and flexor synergies during 37 
gait using EMG  in children with CP, they reported a significant cross-correlation 38 
between extensor synergy activity measured using EMG and the m-Trost test. They 39 
concluded that ‘EMG measures still may be useful for selective motor control 40 
measurement because it measures selectivity at the level of the specific muscles 41 
involved, provided the appropriate task is used’.33 As walking requires selective as well 42 
as synergistic movements, we considered it not an appropriate task for the assessment 43 
of SVMC. The tasks embedded in the SCALE (isolated single-joint movements) were 44 
developed in accordance with the definition of SVMC.8,37 Combining SCALE’s ratings 45 
for single-joint movements with EMG recordings would further allow for directly 46 
measuring voluntary activation of a muscle even in patients with low muscle strength 47 
(manual muscle test grade of 1), where no real joint movement occurs. 48 
Conclusion  49 
This systematic review revealed a limited number of psychometric studies evaluating 1 
the validity and reliability of SVMC measures in children with UMN lesions, and no 2 
studies evaluating responsiveness. Currently, the SCALE appeared to have the highest 3 
level of evidence regarding its reliability and construct validity compared to other clinical 4 
and laboratory-based measures of SVMC. However, only by means of reliable, 5 
validated, and responsive SVMC tools used in carefully designed intervention studies, it 6 
will be possible to provide a scientifically rigorous contribution to the ongoing debate 7 
with regard to the possibility to improve SVMC of the lower extremity in children with 8 
UMN lesions. 9 
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Table I: General characteristic, psychometric properties, and clinical utility of SVMC measures 
General Characteristic  Psychometric Properties Clinical Utility 
 
Instrument 
 
Body 
part 
tested 
Scale Outcome Reliability (BoxB)* 
Validity 
(BoxD,F,H)* 
Clarity of 
instructions Format 
Qualifi-
cations Time Costs 
b7600 (control of simple voluntary movements)   
Selective 
Motor 
Control 
ankle ordinal (0-4) 
max 4 points 
leg score 
Inter-rater: fair-good 
Lowing and Carlberg (2009); 
Smits et al. (2010)46,47 
Test-Retest: fair Lowing 
and Carlberg (2009)46 
 
No study excellent assessment not addressed 5 min none 
modified 
Trost test 
ankle, 
knee, 
hip 
ordinal 
(0-2) 
max 8 points 
leg score 
Inter-rater: fair 
Smits et al. (2010)46 No study excellent assessment recommended 15 min none 
Gillett’s 
SMC test 
for all 
joints 
ordinal 
(0-2) 
max 2 points 
per joint No study
 
Construct (only for knee-flexion): 
Manikowska et al. (2016)31 
 
excellent assessment recommended 15 min none 
Selective 
Control 
Assess-
ment of the 
Lower 
Extremity 
toes, 
STJ, 
ankle, 
knee, 
hip 
ordinal 
(0-2) 
max 10 points 
leg score 
 
Inter-rater: good-excellent  
Fowler et al. (2009)37; Balzer et 
al. (2014)44 
Intra-rater: excellent Balzer et 
al. (2014)44 
 
Content: poor (Fowler et al. 
2009)37 
Construct: fair-good Fowler et al. 
(2009)37; Balzer et al. (2015)44; 
Kusumoto et al. (2016)45; Lim et 
al. (2015)43 Cohort: fair-good 
Fowler et al. (2010)38, (*)Fowler 
and Goldberg (2009)40; 
(*)Goldberg et al. (2011)39, Rha et 
al. (2015 and 2016)41,42 
Criterion: excellent Balzer et al. 
(2015)44  
excellent assessment recommended 15 min none 
Kinematic 
ankle interval 
end range 
ROM DE and 
PF 
Test-Retest: good  Engsberg et 
al. (2004)32 
Cohort: fair Engsberg et al. 
(2004)32 excellent 
video recording 
system required 
not 
stated high 
SD relative 
phase 
measure (°) 
No study Cohort: fair Engsberg et al. (2008)34 excellent 
video recording 
system required 
not 
stated high 
swing 
phase 
knee 
interval 
hip-knee-
angle-diagram 
(minimum 
relative phase) 
No study (*)Fowler and Goldberg (2009)40 adequate 3D gait analysis kinematic  required 
not 
stated high 
interval 
knee 
extension 
acceleration  
No study (*)Goldberg et al. (2011)39 adequate 3D gait analysis kinematic required 
not 
stated high 
EMG  
ankle, 
knee, 
hip 
interval 
EMG cross 
correlation: 
thigh and 
extensor 
synergies 
No study Cohort: fair Zwaan et al. (2012)33 adequate 
EMG                   
(plus three-
dimensional gait 
analysis) 
required not stated high 
ROM: range of motion, DE: Dorsal Flexion; PF: Plantar Flexion; SD: Standard Deviation;  (*) studies are listed both for the SCALE and kinematic measures; *COSMIN rating for every item (0-3: 0 = poor; 1 = fair; 2 = good; 3 = 
excellent) overall score for the methodological quality of the psychometric property assessed was determined by taking the lowest score of any items of one box; 26 Table is separated for ICF functions (b7600 and b7300). 
 
 
Table I. (continued)                                                                                                                                                                                                                                                                                                                                      
General Characteristic  Psychometric Properties Clinical Utility 
 
Instrument 
 
Body 
part 
tested 
Scale Outcome Reliability (BoxB)* 
Validity 
(BoxD,F,H)* 
Clarity of 
instructions Format 
Qualifi-
cations Time Costs 
b7300 (power of isolated muscles and muscle groups, muscle activation) 
Torque 
steadiness 
& EMG  
 
ankle interval 
SD of target 
torques: 
DE: 0.1 and 
0.3 Nm/kg 
body weight 
PF: 0.3 and 
0.5 Nm/kg 
body weight 
Test-Retest: good  Bandholm 
et al. (2009)35 
Cohort: fair Bandholm et al. 
(2009)35 
 
excellent 
customized 
equipment, 
isometric torque 
measure  
 (plus EMG) 
required not stated high 
hip, 
knee, 
ankle 
interval 
SD of 
[torque/mean 
torque] *100) 
No study Cohort: fair Arpin et al. (2013)36 excellent 
isokinetic 
dynamometer 
(plus EMG) 
required not stated high 
ROM: range of motion, DE: Dorsal Flexion; PF: Plantar Flexion; SD: Standard Deviation; *COSMIN rating for every item (0-3: 0 = poor; 1 = fair; 2 = good; 3 = excellent) overall score for the methodological quality of the psychometric 
property assessed was determined by taking the lowest score of any items of one box; 26 Table is separated for ICF functions (b7600 and b7300). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table II: Summary study details, COSMIN-, quality and evidence-rating  
   Study Population Construct validity: Hypothesis Testing (BoxF) (I) 
ICF Instrument Study Diagnose Age (SD) n Design Results COSMIN* 
Modified 
COSMIN** 
Quality 
Criteria 
Overall 
evidence 
b7600 
(control of 
simple 
voluntary 
movements) 
 
Selective 
Control 
Assessment 
of the Lower 
Extremity 
(SCALE) 
Fowler et al. 
(2009)37 
spastic CP 
GMFCS I: 
10; II:12; III: 
19; IV:10 
mean 
11y,11m 
(4y,9m) 
51 Construct validity: GMFCS 
SCALE and GMFCS 
sig. rho: -0.83, sig good good + 
+ + 
(SCALE – 
GMFCS) 
Fowler et al. 
(2010)38 
spastic CP 
GMFCSI: 
10; II: 10; 
III:18; IV:9 
mean 
age 
11y9m 
(4y8m) 
48 
Cohort study: 
pathophysiology 
(increased distal 
impairment, in relation 
to impaired 
corticospinal tracts) 
- sig. differences in SCALE joint scores  
overall joint 
- sig. differences between all pairs of hip, 
knee; ankle 
- proximal to distal concordance 
fair good + 
+ +  
(SCALE – 
joint) 
(*)Fowler 
and 
Goldberg 
(2009)40 
spastic CP 
GMFCS I-IV 
range 
6y-21y 15 
Cohort study: 
SCALE and 
correlation interjoint-
coordination hip-knee 
angle diagrams during 
swing phase of gait 
- higher SCALE scores normal hip-knee-
angle-diagram; ROM increased 
- correlation total SCALE score and MRP: 
sig. rho 0.83 
- correlation total SCALE and velocity: rho 
0.66 
poor fair + 
± 
(SCALE – 
knee swing 
phase)  
(*)Goldberg 
et al. 
(2011)39 
spastic CP 
GMFCS I:5; 
II:8; III:5 
mean 
age 
13y8m 
(7y2m) 
18 
Cohort study: 
correlation SCALE 
limb score and total 
swing joint 
contribution/swing 
extension and 
acceleration 
- sig. PCC: 0.85 
- as SCALE scores increased, the swing 
joint movements provided less resistance 
to knee extension 
- SCALE 0-4 = simultaneous hip and knee 
flexion = diminished knee extension 
acceleration 
poor good + 
Rha et al. 
(2015)41 
spastic CP 
GMFCS I-III 
mean 
age 
10y1m  
34 
Cohort study: 
regression: SCALE; 
contracture knee and 
ankle, gait-kinematics 
and muscle-tendon 
length 
- SCALE scores did not sig. correlated with 
the magnitude nor the timing of peak knee 
flexion during swing phase 
fair fair - 
Rha et al. 
(2016) 42 
Cohort study: 
regression: SCALE; 
minimum knee flexion 
angle at initial contact, 
gait-kinematics and 
muscle-tendon length 
- lower SCALE scores sig. correlated (rho -
0.53) with knee flexion during initial 
contact  
- SCALE scores (p=.001) and delayed 
timing in peak knee flexion during swing 
(p=.026) independently predicted knee 
flexion during initial contact  
fair fair + + 
Balzer et al. 
(2015)44 
spastic CP 
GMFCS I: 
23; II:5; III:8; 
IV: 3 
mean 
age 
12y6m 
(3y7m) 
39 
Construct  validity: 
GMFCS, limb 
distribution 
correlations: MAS 
MMT 
- sig. differences between GMFCS levels (I 
vs II), most joint pairs, less and more 
affected leg 
- sig. correlation: MMT  (rho: 0.88) MAS 
(rho: -0.55) 
fair excellent + 
+ +  
(SCALE – 
GMFCS) 
(SCALE-
joint) 
Lim et al.  
(2015)43 
spastic CP  
GMFCS I: 5; 
II:8; III:7; IV: 
3 
mean 
age 
9y3m 
(2y3m) 
23 
Construct  validity:  
SCALE is a valid tool 
to predict the PBS 
sig. differences between hemi- and 
diplegia,  
- sig. correlation for total and itmes SCALE 
vs PBS (rho: 0.62-0.79) 
poor fair + + 
Kusumoto et 
al. (2016)45 
spastic CP  
GMFCS I: 
12; II:19; 
III:9 
mean 
13y3m 
(3y4m) 
40 
Construct  validity: 
correlation between 
SCALE and knee 
extensor strength 
- sig. differences in SCALE scores more 
and less affected leg, no differences for 
knee extensor strength 
- inverse sig. correlation SCAL E and knee 
extensor strength (rho: 0.4) 
poor poor +/- ? 
CP: cerebral palsy; GMFCS: Gross Motor Function Classification Level;  rho: spearman’s rank correlation coefficient; ROM: Range Of Motion; MRP: Minimum Relative Phase (measurement of interjoint coordination between the hip 
and the knee); PCC: Pearson product-moment correlation coefficient;  MAS: Modified Ashworth Scale; MMT: Manual Muscle Testing; PBS: Pediatric Berg Balance Scale; (*) studies are listed both for the SCALE and kinematic 
measures; *COSMIN rating for every item (0-3: 0 = poor; 1 = fair; 2 = good; 3 = excellent) overall score for the methodological quality of the psychometric property assessed was determined by taking the lowest score of any items of 
one box; 26 ** modified COSMIN: omitting the sample size item boxB03; Quality Criteria: according to Terwee et al. 28 (Appendix 2): + = positive rating; ? = indeterminate rating; - = negative rating; Overall evidence; according to 
Cochrane van Tulder et al. 200329 (Appendix 3): strong (+++/---), moderate (++/--), limiting (+/-) = positive/ negative results; ± conflicting results; ? = unknown results. 
  
                                                                                                                                                                                                                                                                                                                                                                           
CP: cerebral palsy; TD: Typically Developed children; GMFCS: Gross Motor Function Classification Level; SD: Standard Deviation; DE: Dorsal Extension; PF: Plantar Flexion; SDR: Selective Dorsal Rhizotomy; ROM: Range Of 
Motion; GMFM: Gross Motor Function Measure; CV: average coefficient of variation; rho: spearman’s rank correlation coefficient; (*) studies are listed both for the SCALE and kinematic measures; *COSMIN rating for every item (0-
3: 0 = poor; 1 = fair; 2 = good; 3 = excellent) overall score for the methodological quality of the psychometric property assessed was determined by taking the lowest score of any items of one box; 26 ** modified COSMIN: omitting 
the sample size item boxB03; Quality Criteria: according to Terwee et al. 28 (Appendix 2): + = positive rating; ? = indeterminate rating; - = negative rating; Overall evidence; according to Cochrane van Tulder et al. 200329 (Appendix 
3): strong (+++/---), moderate (++/--), limiting (+/-) = positive/ negative results; ± conflicting results; ? = unknown results; Table is separated for ICF functions (b7600 and b7300). 
Table II. (continued)                                                                                                                                                                                                                                                                                                                                       
   Study Population Construct validity: Hypothesis Testing (BoxF) (II) 
ICF Instrument Study Diagnose Age (SD) n Design Results COSMIN* 
Modified 
COSMIN** 
Quality 
Criteria 
Overall 
evidence 
 
b7600 
(control of 
simple 
voluntary 
movements) 
 
Gillett’s SMC 
test 
Mani-
kowska  
et al. 
(2016)31 
CP 
GMFCS I-III 
CP 
mean 
age 15y 
(5y5m);  
TD 22y 
(1y5m) 
CP 23 
TD 19 
Observational 
study: CP muscle 
activity  (EMG) 
during selective 
knee flexion 
versus neuro-
logical intact 
controls 
sig. differences between CP and Control, 
and between CP and different levels of 
SVMC (0 vs 2)  
poor poor + ? 
Kinematic 
 
Engsberg 
et al. 
(2008)34 
spastic CP 
bilateral 
GMFCS I: 5; 
II: 8; III:1 
CP 
mean 
age 16y 
(10y); 
TD age 
15y (9y) 
CP 29 
TD 15 
Cohort study: 
relative phase = 
quantification of 
the relative timing 
between a pair of 
oscillators at the 
same frequency 
- sig. differences between CP (high SD) 
and TD (low SD) children in DE / PF 
movements 
- no sig. differences for antiphase 
movement 
 
poor fair + ± 
Engsberg 
et al. 
(2004)32 
CP pre post 
SDR 
spastic CP 
 
CP 
mean 
age 7y;  
TD 
mean 
age 
7y2m 
CP pre 
post 
SDR 12 
CP 14 
TD 20 
Cohort study:  
differences 
between active 
ROM ankle in CP 
children pre and 
post SDR and vs 
TD 
- sig. increase in active full ROM and 
active DE (but not PF) pre vs post SDR 
- no sig. differences  in CP only group 
- sig. smaller ROM CP vs TD 
poor fair +/- (sample size) 
(*)Fowler 
and 
Goldberg 
(2009)40 
spastic CP 
GMFCS I-IV 
range 
6y-21y 15 
Cohort study: 
correlation  
interjoint-
coordination hip-
knee angle 
diagrams during 
swing phase of 
gait with total limb 
SCALE score 
- higher SCALE scores normal hip-knee-
angle-diagram; ROM increased 
- correlation MRP and SCALE score: sig. 
rho 0.83 
poor fair + + 
(*)Goldber
g et al. 
(2011)39 
spastic CP 
GMFCS I:5; 
II:8; III:5 
mean 
age 
13y8m 
(7y2m) 
18 
Cohort study: 
correlation knee 
extension 
acceleration 
during swing and 
total limb SCALE 
score 
- sig. PCC: 0.85 
- as SCALE scores increased, the swing 
joint movements provided less resistance 
to knee extension 
- SCALE 0-4 = simultaneous hip and knee 
flexion = diminished knee extension 
acceleration 
poor good + + 
EMG 
(thigh- and 
extensor-
synergies) 
Zwaan  
et al. 
(2012)33 
CP post SDR , 
(CP; GMFCS 
I-III) 
CP 
mean 
age 
6y5m;  
TD 
range 6-
11y 
CP post 
SDR  
39 
CP 38 
TD 30 
Cohort study: CP 
vs TD, correlation 
between synergies 
pattern (EMG), 
gait profile, 
mTrost, GMFM 
- extensor synergy: sig. differences CP 
(0.95) vs TD (0.77) 
- thigh synergy: only sig. differences t for 
comfortable speed CP (0.94) vs TD (0.95) 
- no strong correlation between mTrost 
and gait EMG /GMFM 
fair fair +/- ± 
                                                                                                                                                                                                                                                                                                                                                                                
CP: cerebral palsy; TD: Typically Developed children; GMFCS: Gross Motor Function Classification Level; SD: Standard Deviation; DE: Dorsal Extension; PF: Plantar Flexion; SDR: Selective Dorsal Rhizotomy; ROM: Range Of 
Motion; GMFM: Gross Motor Function Measure; CV: average coefficient of variation; rho: spearman’s rank correlation coefficient; FMA: Fugl-Meyer Assessment; *COSMIN rating for every item (0-3: 0 = poor; 1 = fair; 2 = good; 3 = 
excellent) overall score for the methodological quality of the psychometric property assessed was determined by taking the lowest score of any items of one box; 26 ** modified COSMIN: omitting the sample size item boxB03; 
Quality Criteria: according to Terwee et al. 28 (Appendix 2): + = positive rating; ? = indeterminate rating; - = negative rating; Overall evidence; according to Cochrane van Tulder et al. 200329 (Appendix 3): strong (+++/---), moderate 
(++/--), limiting (+/-) = positive/ negative results; ± conflicting results; ? = unknown results; Table is separated for ICF functions (b7600 and b7300). 
      
Table II. (continued)                                                                                                                                                                                                                                                                                                                                      
   Study Population Construct validity: Hypothesis Testing (BoxF) (II) 
ICF Instrument Study Diagnose Age (SD) n Design Results COSMIN* 
Modified 
COSMIN** Quality ICF 
b7300 (power 
of isolated 
muscles and 
muscle 
groups, 
muscle 
activation) 
Torque 
steadiness 
Bandholm 
et al. 
(2009)35 
CP unilateral, 
GMFCS I: 13, 
II:1 
CP 
mean 
age 11y 
(1y); 
TD 
mean 
age 11y 
(1y) 
CP 14 
TD 14 
Cohort study: 
comparison CP 
and TD torque 
steadiness DE/PF 
- sig. reduction of torque steadiness in CP 
(SD and CV were higher) vs TD 
- DE was most affected 
- sig. greater antagonist-agonist activation 
ratio and muscle activation variability in CP 
vs TD 
- DE torque steadiness correlated with 
level of PF coactivation (r = 0.597) and DE 
antagonist-agonist activation ratio                
(r= 0.832) 
poor fair + (sample size) 
Arpin et al. 
(2013)36 
CP bilateral  
and unilateral, 
GMFCS I: 7; 
II:5; III:3 
CP age 
mean 
14y2m 
(7m); 
TD age 
mean 
14y1m 
(7m); 
CP 15 
TD 15 
Cohort study: 
comparison CP 
and TD torque 
steadiness DE/PF 
- sig. greater CV at the ankle in CP vs TD 
- CP: sig. greater variability at ankle, then 
knee and hip 
- CP more regular steady torque patterns 
vs TD 
poor fair  (sample size) 
   Study Population Content Validity (BoxD)  / Criterion Validity (BoxH)  
b7600 
(control of 
simple 
voluntary 
movements) 
 
Selective 
Control 
Assessment 
of the Lower 
Extremity 
(SCALE) 
Fowler et 
al. (2009)37 
spastic CP, 
GMFCS I: 10; 
II:12; III: 19; 
IV:10 
mean 
11y,11m 
(4y,9m) 
51 
Content validity: 
14 experiences 
clinicians  
mean agreement: 91.9% (range 71.4–
100%) for content, administration, and 
grading 
poor/  poor ? ? 
Balzer et 
al. (2015)44 
spastic CP 
GMFCS I: 23; 
II:5; III:8; IV: 3 
mean 
age 
12y6m 
(3y7m) 
39 
Criterion validity: 
correlation SCALE 
and FMA item III & 
IV 
sig. correlation: FMA (rho:0.88)  fair excellent + 
 
++ 
  
 
 
 
Table II. (continued)                                                                                                                                                                                                                                                                                                                                      
 Study Population Reliability (Box B) 
ICF Instrument Study Diagnose Age (SD) n Design Results COSMIN* 
Modified 
COSMIN** 
Quality 
Criteria 
Overall 
evidence 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
b7600 
(control of 
simple 
voluntary 
movements)   
 
Selective 
Motor 
Control test  
(SMC) 
Lowing 
and Carl-
berg 
(2009)46 
CP bilateral 
n=30: 
unilateral  
n=10; 
GMFCS 
I:13; II:12; 
III:10; IV:3 
and V:2 
median 
age 7y; 
range 
3y-16y 
29 Test-Retest (1-60 days) 
Kw ankle DE = 0.88-1;  
RV: 0 - 0.005; RP: -0.11 - 0;                         
RC: 0 - 0.05 (right & left leg scores) 
poor fair + 
+ 
(SMC Test-
Retest) 
40 Interrater  (3 PTs) 
Kw ankle DE: 0.58-0.77  
RV: 0.000-0.030; RP: -0.09 - 0.11;             
RC: -0.26 - 1.16 (right & left leg scores) 
fair good +/- 
- -  
(SMC 
interrater) Selective 
Motor 
Control test 
(SMC) Smits et al. 
(2010)47 spastic CP 
mean 
age 
6y,5m 
(12m)  
21 
Interrater  
(1 PT and 1 Dr) 
1h in-between SMC 
and mTrost 
K ankle DE: 0.55  
95% IC: 0.36-0.74 
(leg total score) 
poor fair - 
Modified 
Trost             
(m-Trost) 
K ankle DE: 0.65; 95% IC: 0.47-0.84 
K knee EXT: 0.69; 95% IC: 0.49-0.88 
K hip ABD: 0.57; 95% IC: 0.37-0.78 
K hip FLEX: 0.71; 95% IC: 0.51-0.91 
poor fair +/- 
- 
(m-Trost 
interrater) 
Selective 
Control 
Assessment 
of the Lower 
Extremity 
(SCALE) 
Fowler et al. 
(2009)37 spastic CP 
mean 
age 
12y,3m  
(5y5m) 
20 
Interrater  
(2 groups: 3 PT and 3 
Dr) 
ICC: 0.88-0.91; 95% CI: 0.69-0-97 
(right & left leg scores) poor good + + + 
(SCALE 
interrater) 
Balzer et al. 
(2015)43 
spastic CP  
GMFCS I: 
23; II:5; III:8; 
IV: 3 
mean 
age 
12y6m 
(3y7m)  
38 
Interrater  
(2 PTs via Video)  
ICC:0.91-0.94 (less & more affected leg); 
MMD: 1.88-1.92 fair excellent + 
Intrarater  
(1 rater via video, 6 
weeks)  
ICC:0.95-0.96 (less & more affected leg); 
MMD: 1.79-1.96 fair good + 
 + + 
(SCALE 
intrarater) 
Kinematic Engsberg et al. (2004)32   Spastic CP 
not 
stated   
(pilot-
study) 
8 Test-Retest (8 weeks) 
sig. PCC: ankle PF: 0.77; ankle DE: 0.94; 
total sagittal range: 0.93 
mean differences of: max PF: 1.6°; DE = 
1.1°; total range = 2.4° 
poor good + 
? 
(sample 
size) 
  (Test-
Retest) 
b7300 (power 
of isolated 
muscles and 
muscle 
groups, 
muscle 
activation) 
Torque 
steadiness 
Bandholm et 
al. (2009)35 CP 
not 
stated   
(pilot-
study) 
7 Test-Retest (1 day) 
ICC ankle PF:0.72; CV < 19% 
ICC ankle DE: 0.31; CV 25%  poor good +/- 
? 
(sample 
size)          
(Test-
Retest) 
CP: cerebral palsy; GMFCS: Gross Motor Function Classification Level; Kw: Kappa weighted; DE: Dorsal Flexion; PF: Plantar Flexion;  RV: Relative rank Variance (random disagreement); RP: Relative Position; RC: Relative 
Concentration (systematic disagreement); PT: Physiotherapist; Dr: Physician; K: Kappa; 95% IC: 95% Confidence interval; EXT: Extension; ABD:  Abduction; FLEX:  Flexion; ICC: Infraclass Correlation Coefficient; MMD: Minimal 
detectable change; PCC: Pearson product-moment correlation coefficient; CV: average coefficient of variation,  *COSMIN rating for every item (0-3: 0 = poor; 1 = fair; 2 = good; 3 = excellent) overall score for the methodological 
quality of the psychometric property assessed was determined by taking the lowest score of any items of one box; 26 ** modified COSMIN: omitting the sample size item boxB03; Quality Criteria: according to Terwee et al. 28 
(Appendix 2): + = positive rating; ? = indeterminate rating; - = negative rating; Overall evidence; according to Cochrane van Tulder et al. 200329 (Appendix 3): strong (+++/---), moderate (++/--), limiting (+/-) = positive/ negative 
results; ± conflicting results; ? = unknown results; Table is separated for ICF functions (b7600 and b7300). 
 
 
 
